These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Revising diagnosis of juvenile idiopathic arthritis in adults: a single-center retrospective study. Felis-Giemza A; Chmurzyńska K; Kołodziejczyk B; Gazda A Rheumatol Int; 2023 Jul; 43(7):1307-1311. PubMed ID: 36859560 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort. Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T; Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291 [TBL] [Abstract][Full Text] [Related]
5. Pharmacosurveillance in Juvenile Idiopathic Arthritis. Shiff NJ; Beukelman T Rheum Dis Clin North Am; 2021 Nov; 47(4):643-653. PubMed ID: 34635296 [TBL] [Abstract][Full Text] [Related]
6. Juvenile idiopathic arthritis: Old disease, new tactics. Momah T; Ray L J Fam Pract; 2019 Mar; 68(2):E8-E13. PubMed ID: 30870545 [TBL] [Abstract][Full Text] [Related]
7. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)]. Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M; Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687 [TBL] [Abstract][Full Text] [Related]
8. Disease activity, treatment and long-term prognosis of adult juvenile idiopathic arthritis patients compared with rheumatoid arthritis patients. Matsumoto T; Matsui T; Hirano F; Tohma S; Mori M Mod Rheumatol; 2020 Jan; 30(1):78-84. PubMed ID: 30499364 [No Abstract] [Full Text] [Related]
9. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care]. Niewerth M; Minden K; Klotsche J; Horneff G Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586 [TBL] [Abstract][Full Text] [Related]
10. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis. Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822 [TBL] [Abstract][Full Text] [Related]
11. Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement. Ho ACH; Wong SN; Leung LCK; Chan WKY; Chong PCY; Tse NKC; Yeung RHM; Kong SY; Lee KP Hong Kong Med J; 2020 Feb; 26(1):56-65. PubMed ID: 32077861 [TBL] [Abstract][Full Text] [Related]
12. Juvenile idiopathic arthritis in the new world of biologics. Ostring GT; Singh-Grewal D J Paediatr Child Health; 2013 Sep; 49(9):E405-12. PubMed ID: 23647810 [TBL] [Abstract][Full Text] [Related]
13. Juvenile idiopathic arthritis - what the clinician needs to know. Kahn PJ Bull Hosp Jt Dis (2013); 2013; 71(3):194-9. PubMed ID: 24151944 [TBL] [Abstract][Full Text] [Related]
14. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis]. Minden K; Klotsche J; Niewerth M; Horneff G; Zink A Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365 [TBL] [Abstract][Full Text] [Related]
15. Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort. Guzman J; Henrey A; Loughin T; Berard RA; Shiff NJ; Jurencak R; Huber AM; Oen K; Gerhold K; Feldman BM; Scuccimarri R; Houghton K; Chédeville G; Morishita K; Lang B; Dancey P; Rosenberg AM; Barsalou J; Bruns A; Watanabe Duffy K; Benseler S; Duffy CM; Tucker LB; J Rheumatol; 2019 Jun; 46(6):628-635. PubMed ID: 30647178 [TBL] [Abstract][Full Text] [Related]
16. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940 [TBL] [Abstract][Full Text] [Related]
17. [Current therapy of polyarticular forms of juvenile idiopathic arthritis]. Hospach A; Rühlmann JM; Weller-Heinemann F Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886 [TBL] [Abstract][Full Text] [Related]
19. Biologics in Pediatric Rheumatology: Quo Vadis? Sterba Y; Ilowite N Curr Rheumatol Rep; 2016 Jul; 18(7):45. PubMed ID: 27306623 [TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort. Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]